Overall, the synergic combination of Keap1-Nrf2 inhibitors and H2S donors has the potential for ulcerative colitis treatment, and molecular hybridization may be a promising strategy for the therapy of multifactorial inflammatory disease. The gene discussed is KEAP1; the disease is ulcerative colitis.